The upregulation of enolase 3 (ENO3), which encodes the β-subunit of enolase, aggravated the progression of NASH by inducing ferroptosis by increasing GPX4 expression in a NASH mouse model (Lu et al., 2021), suggesting that the inhibition of ENOS might be beneficial for NASH treatment. The gene discussed is GPX4; the disease is metabolic dysfunction-associated steatohepatitis.